Eisai

PTC Therapeutics

Follow

PTC Therapeutics is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC’s ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines.

Lundbeck

Follow

Today, millions of people all over the world live with brain diseases. Every day, at Lundbeck we strive to further understand these diseases, develop the best therapies to treat them and make a difference to people living with them. We are one of the only pharmaceutical companies in the world focusing exclusively on brain diseases, and we’re set apart by our specialization. Our purpose is clear: We are committed to advancing brain health and transforming lives Driven by research… For more than 70 years, we’ve been pushing the boundaries of neuroscience. By combining the logic of science with our passion for making a difference to patients, we’ve pioneered some of the most important and commonly used therapies within antipsychotics and antidepressants. We work closely with patients, healthcare professionals and the neuroscience community to uncover causes and to find new treatments that can bring back quality of life to people living with brain diseases. …raising our voice… When every other organ in our body gets sick, we find compassion and care. When our brain suffers, the world typically turns away. As a global specialist, we owe it to those who live with brain diseases to fight stigma and promote better treatment. That’s why we work to improve understanding and parity of care across communities and societies – so we can empower people and rebuild hope. …giving profit a purpose… The Lundbeck Foundation is the majority owner of Lundbeck. Foundation ownership allows us to stay focused on our areas of specialization. It also means that we are in a position to give back. With donations of approximately DKK 500 million a year to biomedical research, the foundation supports the progress of health science. …and working with one aim. Today, we’re over 5,000 people in +20 countries. We build on our Danish heritage, fostering a culture of collaboration and responsibility. Whether we work in labs or in the field, we all have the same aim: to develop innovative treatments that improve the lives of people living with brain diseases.

Regeneron

Follow

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to 12 medicines approved in the United States and/or other countries and numerous product candidates in development, nearly all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic diseases, infectious diseases and rare diseases. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. We do not interview candidates on Google Hangouts. Any questions about job listings can be directed to candidatesupport@regeneron.com . We also do not hire for “at-home data entry” positions.